|
| Exploring the mechanism of action of Shexiang Baoxin Pills in treating angina pectoris based on untargeted metabolomics |
| Hits 384 Download times 152 Received:April 26, 2025 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2025.10.03 |
| Key Words
Shexiang Baoxin Pill;angina pectoris of coronary heart disease;metabolomics;metabolic pathway |
| Author Name | Affiliation | E-mail | | GUO Ruiying | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China | | | LIU Yijia | Rehabilitation Department, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China | | | WANG Shuo | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
Tianjin University Chest Hospital, Tianjin 300222, China | | | LI Lin | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LIU Fanfan | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | XU Qiang | Cardiology Department, Second Affilitated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China | tcmxuqiang@hotmail.com | | YU Chunquan | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | ycq-4@163.com |
|
| Abstract
|
| Objective To explore the mechanism of action of Shexiang Baoxin Pills(SBP) in the treatment of angina pectoris, and to identify and characterize potential biomarkers associated with its therapeutic effects.Methods A total of 60 patients with angina pectoris were enrolled. Patients were divided into two groups: the SBP group(SBP combined with conventional Western medicine treatment) and the Western medicine-only group(treated with conventional Western medicine alone), with 30 patients in each group. Additionally, 30 healthy individuals were included as the control group. Serum samples from the patients before and after treatment were analyzed using ultra-performance liquid chromatography-mass spectrometry(UPLC-MS/MS) for metabolomic profiling. Multivariate statistical analyses, including principal component analysis(PCA) and orthogonal partial least squares discriminant analysis(OPLS-DA), were conducted. The MetaboAnalyst database was used to identify differentially expressed metabolites and related metabolic pathways. To further assess the diagnostic significance of the selected metabolites for angina pectoris, receiver operating characteristic(ROC) curves were used.Results Compared with the healthy control group, angina pectoris patients exhibited significant clustering on the PCA score plot, indicating substantial differences in their metabolic profiles. A total of 12 metabolites, including α-carboxylic acid, bufotenin, all-trans hexahydro-2H-pyrrolo[3, 4-b]quinolin-2-one, and ganoderic acid α, were found to be altered in the serum of angina pectoris patients. The ROC curve analysis showed that these 12 potential biomarkers exhibited good diagnostic performance for angina pectoris. In the SBP group, 11 out of these 12 differentially expressed metabolites showed reversal, including α-carboxylic acid, bufotenin, all-trans hexahydro-2H-pyrrolo[3, 4-b]quinolin-2-one, ganoderic acid α, propionyl-CoA, SM [d20∶1/20∶5(6E, 8Z, 11Z, 14Z, 17Z)-OH(5)], palmitoyl glucuronide, TG [14∶0/20∶0/14∶1(9Z)], hydroxysphingolipid C24∶1, LacCer(d18∶1/20∶0), and DG(14∶0/0∶0/14∶1n5). These metabolites were associated with five major metabolic pathways: sphingolipid metabolism, aldehyde acid and dicarboxylic acid metabolism, propionate metabolism, β-alanine metabolism, and valine, leucine, and isoleucine metabolism.Conclusion SBP may exert its therapeutic effects in angina pectoris by regulating sphingolipid metabolism, aldehyde acid and dicarboxylic acid metabolism, propionate metabolism, β-alanine metabolism, and valine, leucine, and isoleucine metabolism. |
|
|
|
|
|
|
|
